5,106 results match your criteria: "TATA Memorial Hospital[Affiliation]"

Unlabelled: Brain metastases (BMs) are the most common central nervous system (CNS) neoplasms, with an increasing incidence that is due in part to an overall increase in primary cancers, improved neuroimaging modalities leading to increased detection, better systemic therapies, and longer patient survival.

Objective: To identify cancer patients at a higher risk of developing CNS metastases and to evaluate associated prognostic factors.

Methods: Review of imaging referral guidelines, response criteria, interval imaging assessment, modality of choice, as well as the association of clinical, serological, and imaging findings as per various cancer societies.

View Article and Find Full Text PDF

Autophagy-mediated ID1 turnover dictates chemo-resistant fate in ovarian cancer stem cells.

J Exp Clin Cancer Res

August 2024

Imaging Cell Signalling & Therapeutics Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, 410210, India.

Background: The mechanisms enabling dynamic shifts between drug-resistant and drug-sensitive states in cancer cells are still underexplored. This study investigated the role of targeted autophagic protein degradation in regulating ovarian cancer stem cell (CSC) fate decisions and chemo-resistance.

Methods: Autophagy levels were compared between CSC-enriched side population (SP) and non-SP cells (NSP) in multiple ovarian cancer cell lines using immunoblotting, immunofluorescence, and transmission electron microscopy.

View Article and Find Full Text PDF

Intraoperative surgical navigation as a precision medicine tool in sinonasal and craniofacial oncologic surgery.

Oral Oncol

October 2024

Section of Otorhinolaryngology - Head and Neck Surgery, Department of Neurosciences, University of Padua, Padua, Italy; Unit of Otorhinolaryngology - Head and Neck Surgery, Azienda Ospedale Università Padova, Padua, Italy; Guided Therapeutics (GTx) Program International Scholarship, University Health Network (UHN), Toronto, Canada. Electronic address:

Introduction: Recent evidence supports the efficacy of surgical navigation (SN) in improving outcomes of sinonasal and craniofacial oncologic surgery. This study aims to demonstrate the utility of SN as a tool for integrating surgical, radiologic, and pathologic information. Additionally, a system for recording and mapping biopsy samples has been devised to facilitate sharing of spatial information.

View Article and Find Full Text PDF

Precision Medicine and Clinical Trials in Advanced and Metastatic Oral Cancer.

J Maxillofac Oral Surg

August 2024

Karkinos Healthcare Pvt Ltd, 21st Floor, Rupa Renaissance, D33, Turbhe MIDC Road, Navi Mumbai, Maharashtra 400705 India.

Purpose: Oral cancer is a significant global health concern, with high morbidity and mortality rates, particularly in regions with prevalent tobacco usage such as Asia. Majority of oral cancers are detected at an advanced stage resulting in poor survival outcomes. Moreover, the treatment modalities of oral cancers have remained constant with surgery and concurrent chemoradiotherapy being mainstays of the treatment.

View Article and Find Full Text PDF

Factors Affecting Drain Output in Oral Carcinoma.

J Maxillofac Oral Surg

August 2024

Department of Head and Neck Surgery, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Hospital, Homi Bhabha National Institute, PS Building, ACTREC, Kharghar, Navi Mumbai, Mumbai, Maharashtra 410210 India.

Article Synopsis
  • Advanced oral carcinoma surgery often results in large open areas, leading to complications like seroma and hematoma; closed suction drains help manage these issues by creating negative pressure.
  • A study of 222 patients identified that factors such as type of neck dissection, surgery duration, and blood loss significantly affect postoperative drain volume.
  • Key findings suggest that careful assessment of patient and surgical factors is crucial for determining the optimal timing for drain removal, minimizing complications and enhancing recovery.
View Article and Find Full Text PDF

From trials to statistical insights: Bortezomib's story in childhood T-cell lymphoid malignancies.

Hematol Oncol

September 2024

Department of Pediatric Oncology, ACTREC/Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.

View Article and Find Full Text PDF

Redefining HCC Surveillance in India: A Call for Innovative and Inclusive Strategies.

J Clin Exp Hepatol

June 2024

Department of Digestive Diseases & Clinical Nutrition, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.

Hepatocellular carcinoma (HCC) is one of the top ten leading causes of cancer-related death in India, with recent reports suggesting a rising incidence. Chronic HBV infection is still the commonest cause of HCC in India but the recent surge of MASLD and better control of viral hepatitis is already changing the epidemiology. Most HCC in India are diagnosed at an advanced stage where cure is impossible, and prognosis is poor.

View Article and Find Full Text PDF

Cabazitaxel as a promising therapy for cisplatin-resistant bladder cancer: a preliminary study.

Med Oncol

August 2024

Karkinos Healthcare Pvt Ltd, 21st floor, Rupa Renaissance, D33, Turbhe MIDC road, Navi Mumbai, Maharashtra, 400705, India.

Bladder cancer is a common malignancy worldwide, posing a substantial healthcare challenge. Current standard treatment regimens are primarily based on cisplatin, but their success is often limited by cisplatin resistance and associated toxicities. Therefore, there is an urgent need to develop effective and less toxic therapies as alternatives to cisplatin.

View Article and Find Full Text PDF

Pediatric chronic myeloid leukemia (pCML) is a rare malignancy accounting for only 2%-3% of all childhood leukemias. Due to this rarity, familiarity with pCML is limited among most pediatric practitioners, including even pediatric hemato-oncologists. In low- and middle-income countries (LMICs), limited financial resources and limited data specific to pCML represent obstacles that healthcare providers must face in diagnosing and treating this rare condition in children.

View Article and Find Full Text PDF

Realizing Textbook Outcomes Following Liver Resection for Hepatic Neoplasms with Development and Validation of a Predictive Nomogram.

Ann Surg Oncol

November 2024

Department of Gastrointestinal and Hepatobiliary Surgery, Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India.

Background: 'Textbook Outcome' (TO) represents an effort to define a standardized, composite quality benchmark based on intraoperative and postoperative endpoints. This study aimed to assess the applicability of TO as an outcome measure following liver resection for hepatic neoplasms from a low- to middle-income economy and determine its impact on long-term survival. Based on identified perioperative predictors, we developed and validated a nomogram-based scoring and risk stratification system.

View Article and Find Full Text PDF
Article Synopsis
  • This study evaluated the effectiveness of a combination therapy of bevacizumab and erlotinib compared to active surveillance in patients with advanced biliary tract cancers who had stable disease after 6 months of gemcitabine-based chemotherapy.
  • The study randomly assigned 98 patients to either treatment arm and found that those receiving the combination therapy had a median progression-free survival of 5.3 months versus 3.1 months for the surveillance group.
  • The side effects were generally manageable, suggesting that the combination therapy is a viable option for improving patient outcomes in this context.*
View Article and Find Full Text PDF

This report summarizes the status of pediatric surgical oncology services in low- and middle-income countries. Factors such as surgical capacity and enablers, and barriers to providing pediatric surgical oncology services are discussed. A review of the literature was conducted to examine the evidence for the capacity of low- and middle-income countries to provide childhood cancer surgery services, focusing on general surgery.

View Article and Find Full Text PDF

Prevalence and types of cancer in older Indians: A multicentric observational study across 17 institutions in India.

Cancer Epidemiol

October 2024

Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, India. Electronic address:

The global demographic and epidemiological transition have led to a rapidly increasing burden of cancer, particularly among older adults. There are scant data on the prevalence and demographic pattern of cancer in older Indian persons. This was a multicentric observational study conducted between January 2019 and December 2020.

View Article and Find Full Text PDF
Article Synopsis
  • No definitive studies previously showed that chemotherapy improved overall survival in advanced esophageal cancer, prompting a Phase III randomized trial comparing best supportive care (BSC) alone to BSC plus weekly paclitaxel.
  • The trial involved 281 patients, revealing that those on chemotherapy experienced a median overall survival of 9.2 months, compared to only 4.2 months for those on BSC.
  • Results showed that chemotherapy significantly improved response rates, progression-free survival, and quality of life, while not increasing severe toxicities, marking it as a valuable treatment option in this population.
View Article and Find Full Text PDF

Objective: To determine the interobserver variability for complications of pancreatoduodenectomy as defined by the International Study Group for Pancreatic Surgery (ISGPS) and others.

Background: Good interobserver variability for the definitions of surgical complications is of major importance in comparing surgical outcomes between and within centers. However, data on interobserver variability for pancreatoduodenectomy-specific complications are lacking.

View Article and Find Full Text PDF

Adjuvant therapy for intermediate risk factors in oral cancer: Can we reach a consensus?

Oral Oncol

October 2024

Director and Surgeon, Division of Head and Neck Oncology, Apollo Cancer Hospitals, Mumbai 400614, India. Electronic address:

Oral carcinoma is a common disease that poses challenges in treatment management, especially for advanced cases. Adjuvant therapies, such as radiation and chemoradiation therapy, are typically used for advanced oral cancer patients. However, there is uncertainty regarding the use of adjuvant therapy for early-stage patients with certain soft histological parameters.

View Article and Find Full Text PDF
Article Synopsis
  • * The survey received an 85% response rate from 98 uropathologists, revealing strong agreement on distinguishing between luminal and basal UC types, but varied opinions on the importance of certain genetic tests like FGFR3 and TERT promoter mutations.
  • * Most uropathologists acknowledged the aggressive nature of tumors with micropapillary features and favored further evaluation and specific molecular testing for aggressive subtypes, indicating a need for improved consensus in UC classification and treatment strategies.
View Article and Find Full Text PDF

Purpose: In the weekly-3-weekly study, cisplatin at 100 mg/m once-every-3-weeks led to superior locoregional control compared with cisplatin 30 mg/m once-a-week in combination with radical radiation for locally advanced head and neck squamous cell carcinoma (LAHNSCC). We report the updated analysis of the study.

Methods And Materials: In this phase 3 open-label noninferiority study conducted between 2013 and 2017, 300 patients with LAHNSCC were randomly assigned to receive cisplatin 100 mg/m once-in-every-weeks or cisplatin 30 mg/m once-a-week, concurrently with radiation.

View Article and Find Full Text PDF

Introduction: To evaluate the efficacy, safety, pharmacokinetics (PK), and immunogenicity of ZRC-3277 (pertuzumab biosimilar) with Perjeta® (pertuzumab) in previously untreated patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).

Patients And Methods: This phase III, multicenter, double-blind study across 38 sites in India randomized (1:1) patients with HER2-positive MBC in either the ZRC-3277 or Perjeta® group. Both groups also received trastuzumab and docetaxel.

View Article and Find Full Text PDF

Background: There is limited data comparing pain management following various minimally invasive oncological surgeries (MIOS). This retrospective audit was planned to determine the severity of pain and to study the analgesic modalities offered to these patients. Secondary objectives included studying opioid requirements, non-opioid analgesics, their side effects, and the influence of comorbidities on the choice of pain modalities.

View Article and Find Full Text PDF

Biomarker Expression and Clinical Outcomes in International Study of Chemoradiation and Magnetic Resonance Imaging-Based Image-Guided Brachytherapy for Locally Advanced Cervical Cancer: BIOEMBRACE.

Int J Radiat Oncol Biol Phys

January 2025

Department of Radiation Oncology, Leiden University Medical Centre, Leiden, The Netherlands; Department of Radiation Oncology, Erasmus University Medical Centre, Rotterdam, The Netherlands. Electronic address:

Purpose: BIOEMBRACE was designed to study the impact of biomarkers in addition to clinicopathological factors on disease outcomes in patients treated with chemoradiation and magnetic resonance imaging (MRI)-guided brachytherapy (BT) for locally advanced cervical cancer in the EMBRACE study.

Methods And Materials: Between 2018 and 2021, 8 EMBRACE-I sites contributed tumor tissue for the immunohistochemistry of p16, PD-L1, and L1CAM. These biomarkers and clinicopathological factors (International Federation of Gynecology and Obstetrics 2009 stage, nodal status, histology, and necrosis on MRI) were analyzed to predict poor response at BT (high-risk clinical target volume [HR-CTV] ≥ 40 cc) at BT) and 5-year local control, pelvic control, and disease-free survival.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess if adding docetaxel (D) to standard chemotherapy regimens improved overall survival (OS) in patients with advanced HER2-negative gastroesophageal junction and gastric adenocarcinomas.
  • Out of 324 patients enrolled, the analysis showed that FOLFOX/CAPOX provided a median OS of 10.1 months, while the DOF/DOX regimen resulted in 8.9 months, with no significant survival advantage from the addition of docetaxel (P = .70).
  • The study also noted higher rates of severe neutropenia and neuropathy in the DOF/DOX group and identified a surprisingly high incidence of BRCA1 and BRCA2 alterations
View Article and Find Full Text PDF

Parathyroid pathologies are suspected based on the biochemical alterations and clinical manifestations, and the predominant roles of imaging in primary hyperparathyroidism are localisation of tumour within parathyroid glands, surgical planning, and to look for any ectopic parathyroid tissue in the setting of recurrent disease. This article provides a comprehensive review of embryology and anatomical variations of parathyroid glands and their clinical relevance, surgical anatomy of parathyroid glands, differentiation between multiglandular parathyroid disease, solitary adenoma, atypical parathyroid tumour, and parathyroid carcinoma. The roles, advantages and limitations of ultrasound, four-dimensional computed tomography (4DCT), radiolabelled technetium-99 (Tc) sestamibi or dual tracer Tc pertechnetate and Tc-sestamibi with or without single photon emission computed tomography (SPECT) or SPECT/CT, dynamic enhanced magnetic resonance imaging (4DMRI), and fluoro-choline positron emission tomography (F-FCH PET) or [C] Methionine (C -MET) PET in the management of parathyroid lesions have been extensively discussed in this article.

View Article and Find Full Text PDF

Pharmacokinetics and clinical outcomes of low-dose nivolumab relative to conventional dose in patients with advanced cancer.

Cancer Chemother Pharmacol

November 2024

Department of Clinical Pharmacology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC) Sector- 22, Kharghar, Navi Mumbai, 410210, India.

Purpose: Nivolumab is approved at various doses, including 3 mg/kg, 240 mg and 480 mg flat doses at various dosing intervals. The concept of low-dose immunotherapy is gaining traction in recent years. However, there is a need to better understand the pharmacokinetics and clinical outcomes at lower doses.

View Article and Find Full Text PDF